Cavedo Enrica, Redolfi Alberto, Angeloni Francesco, Babiloni Claudio, Lizio Roberta, Chiapparini Luisa, Bruzzone Maria G, Aquino Domenico, Sabatini Umberto, Alesiani Marcella, Cherubini Andrea, Salvatore Elena, Soricelli Andrea, Vernieri Fabrizio, Scrascia Federica, Sinforiani Elena, Chiarati Patrizia, Bastianello Stefano, Montella Patrizia, Corbo Daniele, Tedeschi Gioacchino, Marino Silvia, Baglieri Annalisa, De Salvo Simona, Carducci Filippo, Quattrocchi Carlo C, Cobelli Milena, Frisoni Giovanni B
LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine - IRCCS Centro San Giovanni di Dio-FBF, Brescia, Italy Cognition, Neuroimaging and Brain Diseases Laboratory, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM-UMRS 975), Université Pierre et Marie Curie-Paris, France.
LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine - IRCCS Centro San Giovanni di Dio-FBF, Brescia, Italy.
J Alzheimers Dis. 2014;40(4):941-52. doi: 10.3233/JAD-132666.
The North American Alzheimer's Disease Neuroimaging Initiative (NA-ADNI) was the first program to develop standardized procedures for Alzheimer's disease (AD) imaging biomarker collection.
We describe the validation of acquisition and processing of structural magnetic resonance imaging (MRI) in different Italian academic AD clinics following NA-ADNI procedures.
373 patients with subjective memory impairment (n = 12), mild cognitive impairment (n = 92), Alzheimer's dementia (n = 253), and frontotemporal dementia (n = 16) were enrolled in 9 Italian centers. 22 cognitively healthy elderly controls were also included. MRI site qualification and MP-RAGE quality assessment was applied following the NA-ADNI procedures. Indices of validity were: (i) NA-ADNI phantom's signal-to-noise and contrast-to-noise ratio, (ii) proportion of images passing quality control, (iii) comparability of automated intracranial volume (ICV) estimates across scanners, and (iv) known-group validity of manual hippocampal volumetry.
Results on Phantom and Volunteers scans showed that I-ADNI acquisition parameters were comparable with those one of the ranked-A ADNI scans. Eighty-seven percent of I-ADNI MPRAGE images were ranked of high quality in comparison of 69% of NA-ADNI. ICV showed homogeneous variances across scanners except for Siemens scanners at 3.0 Tesla (p = 0.039). A significant difference in hippocampal volume was found between AD and controls on 1.5 Tesla scans (p < 0.001), confirming known group validity test.
This study has provided standardization of MRI acquisition and imaging marker collection across different Italian clinical units and equipment. This is a mandatory step to the implementation of imaging biomarkers in clinical routine for early and differential diagnosis.
北美阿尔茨海默病神经影像倡议（NA-ADNI）是首个制定阿尔茨海默病（AD）影像生物标志物采集标准化程序的项目。
我们描述了按照NA-ADNI程序在意大利不同学术性AD诊所对结构磁共振成像（MRI）采集和处理的验证情况。
373例主观记忆障碍患者（n = 12）、轻度认知障碍患者（n = 92）、阿尔茨海默病痴呆患者（n = 253）和额颞叶痴呆患者（n = 16）被纳入9个意大利中心。还纳入了22名认知健康的老年对照者。按照NA-ADNI程序进行MRI站点资格认定和MP-RAGE质量评估。有效性指标包括：（i）NA-ADNI体模的信噪比和对比噪声比，（ii）通过质量控制的图像比例，（iii）不同扫描仪间自动颅内体积（ICV）估计值的可比性，以及（iv）手动海马体积测量的已知组有效性。
体模和志愿者扫描结果显示，I-ADNI采集参数与排名靠前的ADNI扫描参数相当。与NA-ADNI的69%相比，I-ADNI MPRAGE图像的87%被评为高质量。除3.0特斯拉的西门子扫描仪外，ICV在不同扫描仪间显示出均匀的方差（p = 0.039）。在1.5特斯拉扫描中，AD组和对照组之间的海马体积存在显著差异（p < 0.001），证实了已知组有效性测试。
本研究实现了意大利不同临床单位和设备间MRI采集和影像标志物采集的标准化。这是在临床常规中实施影像生物标志物进行早期和鉴别诊断的必要步骤。
